Valeant Pharmaceuticals’ Baush & Lomb in 4Q17 and 2017
In 4Q17, Valeant Pharmaceuticals’ (VRX) subsidiary Bausch & Lomb reported revenues of $1.2 billion compared to $1.3 billion in 4Q16. That was a 3% growth on a YoY (year-over-year) basis and a 2% growth quarter-over-quarter.